Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M146Revenue $M0.0Net Margin (%)-303,930.0Z-Score15.7
Enterprise Value $M85.2EPS $-1.3Operating Margin %-303,930.0F-Score3
P/E(ttm))0Cash Flow Per Share $-1.0Pre-tax Margin (%)-243,950.0Higher ROA y-yY
Price/Book2.410-y EBITDA Growth Rate %-16.1Quick Ratio14.9Cash flow > EarningsY
Price/Sales05-y EBITDA Growth Rate %-21.4Current Ratio14.9Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-38.9Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)3ROE % (ttm)-40.9Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M23.1ROI % (ttm)-56.0Gross Margin Increase y-yN

Gurus Latest Trades with RPRX

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found!

RPRX is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


RPRX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Masterson Nola EDirector 2014-09-15Buy200$14.34-56 view
Anderson KatherineCFO 2014-08-14Buy2,000$13.85-54.44 view
PODOLSKI JOSEPHPresident and CEO 2014-08-14Buy2,100$13.91-54.64 view
CAIN DANIEL FDirector 2013-11-12Buy500$14.97-57.85 view
PODOLSKI JOSEPHPresident and CEO 2013-10-25Buy3,000$18.03-65 view
Anderson KatherineCFO 2013-10-25Buy1,000$17.9-64.75 view
Anderson KatherineCFO 2013-10-10Buy1,000$23.77-73.45 view
Anderson KatherineCFO 2013-02-01Buy1,000$11.89-46.93 view
PERCEPTIVE ADVISORS LLC10% Owner 2012-05-14Buy59,500$7.38-14.5 view
PERCEPTIVE ADVISORS LLC10% Owner 2012-05-11Buy170,000$6.35-0.63 view

Press Releases about RPRX :

    Quarterly/Annual Reports about RPRX:

    News about RPRX:

    Articles On GuruFocus.com
    comment on RPRX Mar 06 2013 
    Weekly CFO Buys Highlight: RPRX, ARCT, LUB, JCS, DCIN Apr 23 2012 
    promotes testosteron Jun 22 2011 
    Repros Therapeutics Inc. Reports Operating Results (10-Q) Nov 10 2010 
    Repros Therapeutics Inc. Reports Operating Results (10-Q) Aug 09 2010 
    Repros Therapeutics Inc. Reports Operating Results (10-Q) May 10 2010 
    Repros Therapeutics Inc. Reports Operating Results (10-Q) Nov 09 2009 
    Repros Therapeutics Inc. Reports Operating Results (10-Q) Aug 17 2009 
    Repros Therapeutics Inc. Reports Second Quarter 2009 Financial Results and Provides Update Aug 17 2009 
    Repros Therapeutics Inc. Reports Operating Results (10-Q) May 11 2009 

    More From Our Partners
    Stocks Hitting 52-Week Lows Oct 17 2014 - BENZINGA
    Morning Market Losers Oct 17 2014 - BENZINGA

    More From Other Websites
    INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000... Oct 17 2014
    Nasdaq stocks posting largest percentage increases Oct 17 2014
    EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Repros... Oct 17 2014
    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Repros... Oct 17 2014
    REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure Oct 17 2014
    Repros Therapeutics shares drop on drug application setback Oct 17 2014
    [$$] Repros Therapeutics Shares Drop Premarket Oct 17 2014
    Upcoming FDA Meeting to be Type C Meeting Oct 16 2014
    Upcoming FDA Meeting to be Type C Meeting Oct 16 2014
    Can Repros Therapeutics Shares Still More Than Double? Sep 29 2014
    Repros Therapeutics (RPRX) Worth Watching: Stock Up 17% Sep 29 2014
    US STOCKS-Biotech among biggest Nasdaq gainers Sep 26 2014
    REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure Sep 26 2014
    FDA Schedules Type B Pre-NDA Meeting With Repros Sep 26 2014
    Androxal(R) Second Pivotal Study Achieves Superiority in Top Line Analysis for Both Co-Primary... Sep 25 2014
    REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure Sep 22 2014
    [$$] FDA Recommendation Doesn't Apply to Androxal, Repros Says Sep 22 2014
    Repros Gives Update on Androxal(R) With Respect to Recent FDA Advisory Panel Outcome and Announces... Sep 22 2014
    Rite Aid Plunges As Full-Year Outlook Dims Sep 18 2014
    Why Repros Therapeutics (RPRX) Stock Plummeted to a One-Year Low Today Sep 18 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK